March 2007

By Nir Kossovsky and Robert Block

Nanotechnology financiers were biting their nails this past October as market forces were engaged by regulatory forces. In the same week, the U.S. Food and Drug Administration (“FDA”) held its first full public meeting on nanotechnology safety and environmental risk, and the Environmental Protection Agency (“EPA”) placed a Notice of Rulemaking regarding nanotech product commercial release requirements in the Congressional Record. Investors see only risk — each of the two agencies has the power to shut down the evolving nanotechnology industry.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

Pay per view ($15.00)